All Comers No More? US FDA AdComm Supports PD-L1 Threshold In Esophageal, Gastric Cancer

 
• By Bridget Silverman

Maturing data supporting first-line indications for Merck’s Keytruda, Bristol’s Opdivo and BeiGene’s Tevimbra show inadequate efficacy for patients at the lowest level of PD-L1 expression in esophageal and gastric cancers.

cancer cells
ODAC members considered PD-1 risk-benefit questions in two types of cancer. • Source: Shutterstock

More from US FDA Performance Tracker

More from US Advisory Committees